FINCH THERAPEUTICS GROUP
1D
1W
1M
3M
YTD
1Y
5Y
ALL
Why Robinhood?
You can watch FNCH and buy or sell other stocks, ETFs, and their options commission-free!About FNCH
Finch Therapeutics Group, Inc. engages in the development of microbiome drugs. Its platform includes Human-First Discovery that enables reverse translation from clinical data to engineer the composition of the microbiome based on disease-modifying mechanisms.
CEOMatthew P. Blischak
CEOMatthew P. Blischak
Employees18
Employees18
HeadquartersSomerville, Massachusetts
HeadquartersSomerville, Massachusetts
Founded2014
Founded2014
Employees18
Employees18
FNCH Key Statistics
Market cap673.07M
Market cap673.07M
Price-Earnings ratio-2.53
Price-Earnings ratio-2.53
Dividend yield—
Dividend yield—
Average volume107.56K
Average volume107.56K
High today$13.98
High today$13.98
Low today$13.56
Low today$13.56
Open price$13.80
Open price$13.80
Volume2.61K
Volume2.61K
52 Week high$13.98
52 Week high$13.98
52 Week low$0.2505
52 Week low$0.2505
Stock Snapshot
FINCH THERAPEUTICS GROUP(FNCH) stock is priced at $13.98, giving the company a market capitalization of 673.07M. It carries a P/E multiple of -2.53.
On 2025-12-13, FINCH THERAPEUTICS GROUP(FNCH) stock traded between a low of $13.56 and a high of $13.98. Shares are currently priced at $13.98, which is +3.1% above the low and 0.0% below the high.
The FINCH THERAPEUTICS GROUP(FNCH)'s current trading volume is 2.61K, compared to an average daily volume of 107.56K.
In the last year, FINCH THERAPEUTICS GROUP(FNCH) shares hit a 52-week high of $13.98 and a 52-week low of $0.25.
In the last year, FINCH THERAPEUTICS GROUP(FNCH) shares hit a 52-week high of $13.98 and a 52-week low of $0.25.
People also own
Based on the portfolios of people who own FNCH. This list is generated using Robinhood data, and it’s not a recommendation.